Bachem (SIX: BANB) announced today that its Board of Directors has appointed Anne-Kathrin Stoller, currently Head of Bachem Americas and previously the company’s long-standing Chief Marketing Officer (CMO), as its new CEO, effective January 1, 2026. She succeeds Thomas Meier, who, after more than thirty years at Bachem and nearly six years as CEO, has decided to take on a new challenge outside the company.

“Thomas Meier has contributed significantly to Bachem’s continued success. Together with his team, he has achieved a capital-efficient and profitable growth. At the same time, Bachem’s position as an innovative and reliable partner to the pharmaceutical industry has been further strengthened. We would like to express our sincere thanks to Thomas for his many years of service, his leadership and extraordinary contribution to Bachem,“ says Kuno Sommer, Chairman of the Board of Directors of Bachem. He continues: ”I am very pleased that we have been able to appoint Anne-Kathrin Stoller, an experienced and competent successor from within our own ranks, as the new CEO. Anne-Kathrin has an excellent combination of expertise, leadership skills, and customer focus and, together with her colleagues in the Executive Committee, will continue Bachem’s successful course.”

Anne-Kathrin Stoller has been working for Bachem since 2006. After holding various management positions, including Head of Business Development & Sales Europe, Chief Marketing Officer, and member of the Executive Committee, she took on the role of Chief Operating Officer Americas in 2022 and is responsible for the company’s US business. Anne-Kathrin Stoller studied chemistry in Hannover and Cambridge (UK) and holds a doctorate in bioorganic chemistry from the University of Basel.

In English Download
In German Download